Original-Research: Daldrup & Söhne AG - from Quirin Privatbank Kapitalmarktgeschäft
Classification of Quirin Privatbank Kapitalmarktgeschäft to Daldrup & Söhne AG
FY 2024: EBIT more than doubled Daldrup & Söhne closed 2024 extremely successfully: the company managed to increase EBIT from EUR 2.6m (FY 2023) to EUR 6.9m. At EUR 54.6m, its total output was significantly higher than the previous year (EUR 48.4m). The consolidated net profit for the past business year amounted to EUR 2.5m (FY 2023: EUR 0.9m). EPS thus amounted to EUR 0.42 (previous year: EUR 0.15). Its equity ratio is comfortable at 68.8% (previous year: 50.6%). As of the balance sheet date of 31 December 2024, Daldrup also had cash and cash equivalents of EUR 6.4m (previous year: EUR 3.6m). Due to smart working capital management and higher earnings, cash flow from operating activities increased from EUR 3.5m (FY 2023) to EUR 12.1m. After taking investments into account, its free cash flow jumped to EUR 9.7m (previous year: EUR 0.5m). The company was able to turn a net debt position (EUR 4,2m in FY 2023) to a net cash position of EUR 4.8m - a EUR 9m improvement. Guidance: the company expects to generate total output of around EUR 52m in FY 2025 and to achieve an EBIT margin of between 9% and 12% of total output. We regard this outlook to be conservative; one should keep in mind that there is substantial support from the government and state authorities in addition to original, fundamental demand for Daldrup’s services. We therefore confirm our Buy recommendation and increase our TP to EUR 18.00 to reflect its improved cash position. You can download the research here: http://www.more-ir.de/d/32816.pdf For additional information visit our website: https://research.quirinprivatbank.de/ Contact for questions: Quirin Privatbank AG Institutionelles Research Schillerstraße 20 60313 Frankfurt am Main research@quirinprivatbank.de https://research.quirinprivatbank.de/
The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
2152046 06.06.2025 CET/CEST
P R O D U C T S U G G E S T I O N S
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.